Subtopic Deep Dive
TMPRSS2-ERG Gene Fusion
Research Guide
What is TMPRSS2-ERG Gene Fusion?
TMPRSS2-ERG gene fusion is a somatic chromosomal rearrangement occurring in approximately 50% of prostate cancers, fusing the androgen-regulated TMPRSS2 promoter to the ERG oncogene via ETS family rearrangements.
This fusion drives prostate cancer oncogenesis by placing ERG under androgen-responsive control (Tomlins et al., 2007). It defines a distinct molecular subtype with specific genomic and clinical features (Taylor et al., 2010). Over 10 key papers from 2007-2018 characterize its prevalence, mechanisms, and prognostic value.
Why It Matters
TMPRSS2-ERG fusion stratifies prostate cancer into molecular subtypes with differing progression risks, enabling precision diagnostics (Yu et al., 2010). It serves as a biomarker in urine exosomes for non-invasive detection (Nilsson et al., 2009). Targeting fusion-driven pathways could improve therapies for the 50% of cases affected, as shown in genomic profiling of primary and advanced tumors (Taylor et al., 2010; Grasso et al., 2012).
Key Research Challenges
Fusion mechanism heterogeneity
Multiple chromosomal rearrangements create TMPRSS2-ERG fusions, complicating targeted inhibition (Tomlins et al., 2007). Distinct classes of interstitial deletions and insertions drive oncogenesis variably across tumors (Yu et al., 2010).
Prognostic value inconsistency
Fusion presence correlates variably with aggressiveness in primary versus castration-resistant prostate cancer (Grasso et al., 2012). Integrative profiling reveals context-dependent outcomes (Taylor et al., 2010).
Therapeutic targeting barriers
ERG overexpression resists standard androgen deprivation despite androgen regulation (Shen and Abate-Shen, 2010). Network integration with AR and Polycomb shows progression dependencies (Yu et al., 2010).
Essential Papers
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor, Nikolaus Schultz, Haley Hieronymus et al. · 2010 · Cancer Cell · 3.7K citations
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso, Yi-Mi Wu, Dan R. Robinson et al. · 2012 · Nature · 2.6K citations
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Dong Gao, Ian Vela, Andrea Sboner et al. · 2014 · Cell · 1.5K citations
The genomic complexity of primary human prostate cancer
Michael F. Berger, Michael S. Lawrence, Francesca Demichelis et al. · 2011 · Nature · 1.2K citations
Prostate cancer is the second most common cause of male cancer deaths in the United States. However, the full range of prostate cancer genomic alterations is incompletely characterized. Here we pre...
Molecular genetics of prostate cancer: new prospects for old challenges
Michael M. Shen, Cory Abate‐Shen · 2010 · Genes & Development · 943 citations
Despite much recent progress, prostate cancer continues to represent a major cause of cancer-related mortality and morbidity in men. Since early studies on the role of the androgen receptor that le...
Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
Gerhardt Attard, Alison Reid, Timothy A. Yap et al. · 2008 · Journal of Clinical Oncology · 892 citations
Purpose Studies indicate that castration-resistant prostate cancer (CRPC) remains driven by ligand-dependent androgen receptor (AR) signaling. To evaluate this, a trial of abiraterone acetate—a pot...
An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression
Jindan Yu, Jianjun Yu, Ram S. Mani et al. · 2010 · Cancer Cell · 844 citations
Reading Guide
Foundational Papers
Start with Tomlins et al. (2007) for discovery of ETS fusions, then Taylor et al. (2010) for genomic prevalence (3731 citations), and Yu et al. (2010) for AR network integration.
Recent Advances
Study Grasso et al. (2012) on CRPC mutations (2557 citations) and Wang et al. (2018) for advanced genetics (735 citations).
Core Methods
Core techniques: whole-genome sequencing (Berger et al., 2011), organoid modeling (Gao et al., 2014), network analysis (Yu et al., 2010), exosome biomarkers (Nilsson et al., 2009).
How PapersFlow Helps You Research TMPRSS2-ERG Gene Fusion
Discover & Search
Research Agent uses searchPapers('TMPRSS2-ERG fusion prostate cancer') to retrieve Tomlins et al. (2007) as top hit, then citationGraph to map 840+ citing papers, and findSimilarPapers to uncover Yu et al. (2010) network analysis.
Analyze & Verify
Analysis Agent applies readPaperContent on Taylor et al. (2010) to extract fusion prevalence data, verifyResponse with CoVe against Grasso et al. (2012) for consistency in CRPC, and runPythonAnalysis to plot citation trends or fusion frequencies using pandas on exported metadata.
Synthesize & Write
Synthesis Agent detects gaps in therapeutic targeting via contradiction flagging across Shen and Abate-Shen (2010) and Yu et al. (2010); Writing Agent uses latexEditText for manuscript sections, latexSyncCitations to link 3731-cited Taylor et al. (2010), and exportMermaid for fusion network diagrams.
Use Cases
"Analyze TMPRSS2-ERG fusion frequencies across prostate cancer datasets"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas aggregation of mutation data from Taylor 2010 and Berger 2011) → matplotlib frequency plot output.
"Draft LaTeX review on TMPRSS2-ERG prognostic biomarkers"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Tomlins 2007, Nilsson 2009) + latexCompile → camera-ready PDF with fused gene diagrams.
"Find code for TMPRSS2-ERG detection in genomic data"
Research Agent → paperExtractUrls (from Gao 2014 organoid methods) → paperFindGithubRepo → githubRepoInspect → verified analysis pipelines for fusion calling.
Automated Workflows
Deep Research workflow scans 50+ TMPRSS2-ERG papers via searchPapers → citationGraph → structured report with GRADE-scored evidence from Taylor et al. (2010). DeepScan applies 7-step CoVe chain to verify fusion-prognosis claims across Grasso et al. (2012) and Yu et al. (2010). Theorizer generates hypotheses on ERG-AR networks from Tomlins et al. (2007) literature synthesis.
Frequently Asked Questions
What defines TMPRSS2-ERG gene fusion?
It is a chromosomal rearrangement fusing TMPRSS2 promoter to ERG ETS oncogene, occurring in 50% of prostate cancers (Tomlins et al., 2007).
What methods detect TMPRSS2-ERG fusions?
Methods include FISH, RT-PCR, and sequencing; urine exosomes enable non-invasive detection (Nilsson et al., 2009; Berger et al., 2011).
What are key papers on TMPRSS2-ERG?
Tomlins et al. (2007, 840 citations) discovered rearrangement classes; Taylor et al. (2010, 3731 citations) profiled in primary tumors; Yu et al. (2010, 844 citations) integrated with AR networks.
What open problems exist?
Challenges include inconsistent prognostic value and therapeutic targeting of fusion-driven oncogenesis (Grasso et al., 2012; Shen and Abate-Shen, 2010).
Research Prostate Cancer Treatment and Research with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching TMPRSS2-ERG Gene Fusion with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.